A month ago the FDA Granted Breakthrough Designation to Ianalumab for Sjögren Disease . The drug targets BAFF and depletes B cells. Two recent positive RCTs (NEPTUNUS-1, NEPTUNUS-2). Novartis expects a regulatory decision in early 2026 https://t.co/PXVjGG1Cmd https://t.co/0s5livw1bg

• FDA Grants Breakthrough Designation to Ianalumab for Sjögren Disease

FDA has approved tocilizumab-anoh (Avtozma; Celltrion), a biosimilar to Actemra, for intravenous and subcutaneous use in rheumatoid arthritis (RA), giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and COVID-19. https://t.co/qw7SJ7ZCK9

Taiwan National retrospective study (2001-20) of 8732 newly Dx, biologic-naïve RA pts initiating b/tsDMARDs. Found no difference in malignancy event rates between DMARDs. 2.16% over 5-yr & 2.89% over 18yrs. (6384 Rx w/ TNFis, 667 w/ TCZ, 656 w/ ABA, 1025 on tsDMARDs) https://t.co/54ZMPywEYI

Should I become a physician or physician assistant/associate? Practical overview from US News. KEY QUESTIONS: 1) which is harder to get into? 2) Career flexibility? 3) Work-Life balance? 4) Which fits for you? Both are a lifelong commitment to patient care. https://t.co/szv1nUmkYQ

Is Giant cell arteritis over diagnosed or over-referred? Caution IF the patient is: 1) under age 50yrs; 2) has Hx of chronic HA or migraine; 3) has normal ESR/CRP. Why not consider screen w/ Giant Cell Arteritis Probability Score (needing 9.5/32 points) https://t.co/qnCWgzjYJ4 https://t.co/LT6atm0m8f

• https://buff.ly/90MRmxJ

UK Retrospective analysis of 2 RA cohorts, 2,701 pts (F/U 6 yrs) = 101 (3.7%) Dx with ILD. (12 @ baseline, 46 w/ F/U, 43 @ death). ILD Dx signif. assoc w/ onset age (aOR 1.03), seropositivity (aOR 2.58), ever smoking (aOR 1.7). https://t.co/Zvkb1Wjpa4 https://t.co/YMkWDc3rMr

• Rheumatoid arthritis and interstitial lung disease: the role of comorbidities. …

Danish DERMBIO registry of psoriasis pts Rx w/ biologics. Among 3790 bionaive pts ustekinumab had best 1-5 yr survival vs (ADA & SEC). In 3403 bioexperienced pts, bimekizumab, guselkumab, & risankizumab had highest 2-year drug survival rate. https://t.co/TInyLPMYkb https://t.co/UTPqa9erPU

• Biologic Survival in Bionaive and Bioexperienced Patients With Psoriasis

AMA survey of 502 nurse practitioners (95% work on a MD-led team - 88% were satisfied; Half very satisfied working w/ MDs. 94% valued physician mentorship;  89% cited patient safety as a key benefit to physician-led care; and  88% listed liability protection as a key benefit. https://t.co/SVvr3XEQSz

American College of Chest Physicians has announced that advanced practice providers (APPs) can earn the CHEST Critical Care Advanced Practice Provider (CCAPP) designation; CCAPP Certification exam designed to validate clinical competence & Enhanced credibility/recognition https://t.co/Ip6YMjwOBc

FDA Commissioner Marty Makary is seeking to make more drugs available without a prescription; and has stated “everything should be over-the-counter” unless the drug is addictive, unsafe, or requires monitoring. https://t.co/CGurlOWO8m https://t.co/bFwkpZ3kbn

• FDA Push for Nonprescription Drugs Risks Cost Shift to Consumers

Full read review of JAK inhibitors. JAK inhibitors have a reasonably rapid onset of action and a short half-life, which facilitates management of any adverse effects. The half-life of Tofacitinib, Baricitinib & Upadacitinib is 3 hrs, 13 hrs. & 9-14hrs. https://t.co/jKO2LL2TVC

Epidemiology of Dry Eye Autoimmune Disease Rates upwards of 20% were seen across nine common autoimmune diseases other than Sjögren's, most often in rheumatoid arthritis (39.3%) with Crohn's disease bringing up the rear (23.0%), according to Chi-Chin Sun, MD, PhD, of Chang Gung https://t.co/lnacSUlrI8

Congratulations to Dr. Kevin Tracey for being named toTIME100 2026 Health list. He is president & CEO of the Feinstein Institutes for Medical Research and helped develop vagal N. Stimulation in RA from SetPoint https://t.co/rgtVUldNLt https://t.co/Y4ka9GSORx

• https://buff.ly/jw8RofI

Case-control study of 72 estab. & 56 early RA pts the diagnostic performance of 14-3-3η testing showed AUC ≥0.85 for early & estab.RA. Early RA, -CCP had better specificity (96.4%) and a positive likelihood ratio (21.2%), while 14-3-3η had higher sensitivity (88.1%) https://t.co/jaUux9quy6